According to WHO Director-General Tedros Adhanom Ghebreyesus, antimicrobial resistance is "one of the greatest health threats humanity faces today".

The Center for Disease Control and Prevention (CDC) estimates that each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. The reality is, #AMR can affect anyone.

At Botanix, we are working proactively to develop alternatives for broad-spectrum antibiotics in the clinic. Our BTX 1801 pipeline is focused on testing the capabilities of synthetic cannabidiol for fighting antibiotic resistance, and to develop a novel platform product for multiple human and animal health applications.

Spread awareness, stop resistance.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Botanix Pharmaceuticals Ltd. published this content on 23 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 December 2021 14:30:04 UTC.